ONESOURCE
Invest with MTF
Invest Now
Invest in OneSource Specialty Pharma with 3.12X leverage
Performance
- Low
- ₹1,732
- High
- ₹1,869
- 52 Week Low
- ₹1,210
- 52 Week High
- ₹2,248
- Open Price₹1,732
- Previous Close₹1,732
- Volume735,225
Investment Returns
- Over 1 Month -5.23%
- Over 3 Month -6.77%
- Over 6 Month + 9.61%
- Over 1 Year + 4.79%
Smart Investing Starts Here Start SIP with OneSource Specialty Pharma for Steady Growth!
OneSource Specialty Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 501.6
- PEG Ratio
- 4.2
- Market Cap Cr
- 20,042
- P/B Ratio
- 3.4
- Average True Range
- 56.53
- EPS
- 12.04
- Dividend Yield
- 0
- MACD Signal
- -13.87
- RSI
- 35.1
- MFI
- 54.4
OneSource Specialty Pharma Financials
OneSource Specialty Pharma Technicals
EMA & SMA
Current Price
₹1,750.00
+
18
(1.04%)
- Bearish Moving Average 16
- Bullish Moving Average 0
- 20 Day
- ₹1,800.27
- 50 Day
- ₹1,828.74
- 100 Day
- ₹1,821.51
- 200 Day
- ₹1,756.76
Resistance and Support
1730.4
- R3 1,762.40
- R2 1,751.20
- R1 1,741.60
- S1 1,720.80
- S2 1,709.60
- S3 1,700.00
OneSource Specialty Pharma Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2025-11-11 | Quarterly Results | |
| 2025-08-04 | Quarterly Results | |
| 2025-05-05 | Audited Results | |
| 2025-01-29 | Quarterly Results |
OneSource Specialty Pharma F&O
About OneSource Specialty Pharma
- NSE Symbol
- ONESOURCE
- BSE Symbol
- 544292
- Managing Director & CEO
- Mr. Neeraj Sharma
- ISIN
- INE013P01021
Similar Stocks to OneSource Specialty Pharma
OneSource Specialty Pharma FAQs
OneSource Specialty Pharma share price is ₹1,750 As on 17 November, 2025 | 15:26
The Market Cap of OneSource Specialty Pharma is ₹20041.9 Cr As on 17 November, 2025 | 15:26
The P/E ratio of OneSource Specialty Pharma is 501.6 As on 17 November, 2025 | 15:26
The PB ratio of OneSource Specialty Pharma is 3.4 As on 17 November, 2025 | 15:26
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.